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Objective: Osteoarthritis (OA) is a degenerative disease of joint tissues that causes articular cartilage
erosion, osteophytosis and loss of function due to pain. Inﬂammation and inﬂammatory cytokines in
synovial ﬂuid (SF) contribute to OA progression. Intra-articular (IA) injections of multipotent mesen-
chymal stromal cells (MSCs) are employed to treat OA in both humans and animals. MSCs secrete
paracrine pro-inﬂammatory and anabolic signaling molecules that promote tissue repair. The objective of
this study was to investigate the effects of OASF on the gene expression of paracrine signaling molecules
by MSCs.
Methods: The effects of Lipopolysaccharide (LPS) and interleukin (IL)-1b as well as both normal (N) and
osteoarthritis (OA) SF stimulations on the expression of paracrine pro-inﬂammatory (tumor necrosis
factor (TNF)-a, IL-1b, IL-8), modulatory (IL-6) and anabolic (vascular endothelial growth factor (VEGF),
transforming growth factor (TGF)-b1 and insulin-like growth factor (IGF)-1) signaling molecules by
equine bone marrow multipotent mesenchymal stromal cells (eBM-MSCs) was investigated employing
reverse transcriptase-polymerase chain reaction (RT-PCR).
Results: In contrast with NSF, OASF signiﬁcantly up-regulated the expression of VEGF in eBM-MSCs. Both
NSF and OASF signiﬁcantly down-regulated the expression of IL-1b. LPS and IL-1b signiﬁcantly increased
the expression of pro-inﬂammatory cytokines (TNF-a, IL-8 and IL-6; and IL-1b and IL-8 respectively).
Discussion: We conclude that the transcription of paracrine signaling molecules in eBM-MSCs is
modulated by SF. Furthermore, OA alters the properties of SF and the response of eBM-MSCs. Finally, the
effects of LPS or IL-1b stimulation are distinct to that observed following stimulations with OASF.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Multipotent mesenchymal stromal cells (MSCs) secrete trophic
factors with anti-inﬂammatory properties
In recent years, there has been a paradigm shift in the under-
standing of multipotent MSCs potential therapeutic mechanisms:
They may exert their effects by environment-dependent secretion
of paracrine signaling molecules rather than differentiation into
target tissue cells1,2. MSCs undergo genome-wide expression
changes in an inﬂammatory microenvironment3,4 and secreteto: S. Laverty, Comparative
ciences cliniques, Faculté de
00, St Hyacinthe, Québec J2S
78-8158.
verty).
s Research Society International. Pparacrine signaling molecules that modulate the innate immune
response and trophic factors that inﬂuence cell response to
injury5,6. Evidence, from both in vitro and in vivo studies, suggests
that MSCs may act as cellular sentinels of inﬂammation and tissue
damage that respond by secreting a plethora of signaling molecules
that may also assist tissue repair7. These molecules include growth
factors such as vascular endothelial growth factor (VEGF), insulin-
like growth factor 1 (IGF-1) and transforming growth factor b
(TGF-b1)8,9, cytokines such as TNF-a and interleukin (IL)-6 and
chemokines such as IL-83,10. These molecules inﬂuence a wide
range of biological processes that include proliferation, differenti-
ation, migration, and apoptosis.
MSC therapy for osteoarthritis (OA)
OA is a progressive, degenerative disease of joint tissues that
results in a characteristic articular cartilage erosion, osteophytosisublished by Elsevier Ltd. All rights reserved.
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drocyte loss are characteristic features of this disease. Inﬂammation
is also recognized as an important component of the pathobiology
of OA and IL-1b, TNF-a and IL-6 were shown to be key cytokines
involved in OA11. IL-1b itself drives the degradation of the articular
cartilage matrix12. An optimal therapeutic approach to OA would
ideally reduce joint inﬂammation and concurrently stimulate joint
tissue repair. Intra-articular (IA) MSC therapy offers this potential.
IA injections of MSCs lead to a signiﬁcant decrease in cartilage
degeneration, subchondral sclerosis, osteophytosis and promote
meniscal regeneration at the site of meniscal resection in surgical
joint instability models13. In addition, MSCs appear to contribute to
the repair of damaged articular tissue13 via their engraftment and
the production of extracellular matrix components locally14. IA BM-
MSCs also produce a signiﬁcant decrease in synovial prostaglandin
e2 (PGE2) levels in OA joints, suggesting that IA eBM-MSCs have the
capacity to modulate inﬂammation in OA joints15.
As pre-existing joint inﬂammation may impact the secretory
proﬁle of MSCs and alter their therapeutic efﬁcacy16, it is crucial to
determine the effect of inﬂammatory microenvironments on the
expression of paracrine signaling molecules by BM-MSCs. There is
still a considerable knowledge gap concerning the behavior, biology
and effects of IAMSCs, particularly in the context of an injured joint.
This knowledge is essential toward optimization of this form of
therapy.
Synovial ﬂuid (SF) molecules signal to MSCs
Few studies have been conducted on the inﬂuence of SF from
diseased joints on MSC function. Most have focused on the pro-
migratory and differentiation effects of SF on MSCs2,17e20. Healthy
SF contains chemotactic signaling molecules that stimulate MSC
migration, and are signiﬁcantly decreased in OASF and associated
with slower fracture repair17. In vitro stimulation of MSCs with SF
from rheumatoid arthritis joints elicits potent migratory responses
in MSCs, and, to a lesser degree, OASF19. OASF also stimulates the
expansion of synovium-resident MSC populations18. Coleman and
colleagues also reported that 5% SF from OA articulations signiﬁ-
cantly inhibited chondrogenesis in vitro by MSCs2. The changes in
SF composition observed in naturally occurring OA may alter the
gene expression proﬁle of MSCs and their production of paracrine
anabolic and pro-inﬂammatory molecules5,10.
A complete understanding of the inducible changes in gene
expression of MSCs in an IA environment is very important from a
clinical perspective as stem cell therapy is currently being investi-
gated for joint disease therapy with an accompanying inﬂamma-
tory component that could potentially inﬂuence the secretory
proﬁle and subsequent efﬁcacy of the administered cells. Although
it has been previously demonstrated that MSCs react to the pres-
ence of inﬂammatory cytokines and growth factors, the speciﬁc aim
of this study was to characterize the gene expression proﬁle of
equine bone marrow multipotent mesenchymal stromal cells
(eBM-MSCs) to the inﬂammatory molecules present in OASF
in vitro. Using RT-PCR, we studied the expression of paracrine pro-
inﬂammatory molecules such as cytokines and chemokines (IL-1b,
TNF-a, IL-6 and IL-8) as well as paracrine anabolic molecules (TGF-
b1, VEGF, IGF-1) in eBM-MSCs in response to stimulation with
lipopolysaccharide (LPS), IL-1b or SF from healthy and OA-affected
articulations.
Materials and methods
Experimental procedures performed were approved by the
Animal Care and use Committee of the Faculty of Veterinary
Medicine, Université de Montréal.Collection of SF
Equine limbs were obtained from a local abattoir. SF was asep-
tically harvested from normal (NSF: N ¼ 3) or OA (OASF: N ¼ 2)
joints based on the macroscopic appearance (presence of articular
cartilage erosions and osteophytes) of the articular surfaces.
SF samples were transferred to heparin-treated tubes, were
ﬁlteredwith 45 mm ﬁlters and centrifuged at 1500 rpm for 12min at
12C (Beckman Coulter, Brea, California, USA). Aliquots were stored
at 20C.
MSC isolation and culture
Bone marrow samples from healthy horses (n ¼ 3) (6e9 years
old) were harvested in heparinized tubes, and eBM-MSCs were
isolated using gradient density separation techniques as described
previously21.
Induction of MSC into mesenchymal lineages
eBM-MSCs differentiation into adipocyte, osteoblast and chon-
drocyte lineages was conﬁrmed as we described previously21 (data
not shown).
MSC stimulation
eBM-MSCs from each horse were seeded, separately, in six-well
dishes. When the cells reached 80% conﬂuence, undifferentiated
cells were washed with Dulbecco’s phosphate buffered saline
(DPBS) and stimulated with LPS (100 ng/ml) (SigmaeAldrich,
Oakville, On; Clone number 0127:B8), IL-1b (10 ng/ml) (Sigmae
Aldrich, catalogue# I9401) and SFs either normal (NSF) or OA
(OASF) following ﬁltration through 0.45 mm ﬁlters (Sarstedt).
Unstimulated wells served as controls. Cells from all horses were
subjected to each condition (including stimulations and control
untreated) in duplicate wells. LPS, a bacterial endotoxin, is a
recognized stimulus for in vitro models of inﬂammation and in-
duces the expression of pro-inﬂammatory cytokines at this con-
centration in equine species22. The dose of IL-1b (10 ng/ml)
was employed as it is frequently used to model OA in vitro23.
10% SF dilutions were employed as described by Song and
colleagues19.
Each treatment was carried out in duplicate for 1, 3, 6, 12 and
24 h in a total volume of 2.5ml per well. At experimental endpoints,
cells were washed with DPBS and incubated at 37C for 7 min with
1.5 ml of trypsin 0.25% (Invitrogen) per well to detach adherent
cells from the culture surface. The cells were collected, duplicates
were pooled and centrifuged at 1500 rpm for 10 min at 18C. The
supernatant was discarded and the pellet was resuspended in 1 ml
of media and transferred to a 2 ml Eppendorf tube and centrifuged
for 2 min.
Ribonucleic acid (RNA) extraction and complementary
deoxyribonucleic acid (cDNA) synthesis
Each cell pellet from pooled duplicates was resuspended in 1 ml
of Trizol Reagent (Invitrogen) and total RNA was extracted ac-
cording to the manufacturer’s instructions. RNA concentration in
diethylpyrocarbonate (DEPC)-treated H2O was measured spectro-
photometrically (Nanodrop1000, ThermoScientiﬁc, Wilmington,
DE, USA). We then reverse transcribed 2 mg into cDNA using the
Superscript III Reverse Transcription System (Invitrogen) in the
presence of RNasin Ribonuclease Inhibitor (60 U, Promega, Fisher
Scientiﬁc) using oligo(dT)12e18 primers (500 ng, Invitrogen) in a
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to a total volume of 120 ml (4 dilution) with RNAse-free water.
Quantitative PCR (qPCR)
The cDNA from pooled duplicate cells of each horse was used to
assess the levels of each gene of interest outlined above using qPCR.
For each gene of interest and housekeeping genes, cDNA from each
horse was studied in duplicates. Pipetting of the reaction mix was
performed using the QiAgility (Qiagen, Mississauga, ON, Canada)
and in duplicate. qPCR was performed using a RotorGene thermal
cycler (Rotor-Gene Real-Time Centrifugal DNA Ampliﬁcation Sys-
tem 3000, Corbett Research, Montreal Biotech, Montreal, QC,
Canada) and the Quantitect SYBR Green PCR kit (Quantitect SYBR
Green PCR kit, Qiagen, Mississauga, ON, Canada). Reactions were
run in a volume of 20 ml using 4 ml of diluted cDNA. The concen-
tration of oligonucleotide primers in each reaction was 5 mM. The
ampliﬁcation protocols are listed in Table I. Finally a melting curve
using 0.5C steps of 10 s duration starting from 57C was
determined.
Quantiﬁcation was performed using optimized gene-speciﬁc
standard curves made of serial dilutions (10) of polymerase
chain reaction (PCR) products (QIAGEN’s Gel Extraction Kit) with
reproducible efﬁciency coefﬁcients between 95% and 105% and a
calibrator sample in the target run. Absolute values were corrected
relative to ubiquitin expression used as a reference gene. The
equine speciﬁc primers for paracrine pro-inﬂammatory cytokines
(TNF-a, IL-1b, IL-8), themodulatory cytokine (IL-6) and the anabolic
signaling molecules (VEGF, IGF-1 and TGF-b1) employed are listed
in Table I.
Statistical analysis
qPCR data is reported asmean (N¼ 3) fold increase representing
the ratio of stimulated cell normalized gene expression over control
unstimulated cell normalized gene expression (corresponding to a
value of 1). The resulting fold increase values were transformed to a
log scale, and a repeated-measures analysis of variance (ANOVA)
analysis was performed to investigate the effects of stimulations
(LPS, IL-1b, NSF and OASF) and timepoints (1, 3, 6, 12 and 24 h). 95%
conﬁdence intervals are provided for the fold increases or de-
creases. A priori contrasts were carried out between pairs of means,
and alpha levels for each comparison were adjusted using the
sequential Bonferroni procedure. Statistical analyses were carried
out with SAS v. 9.3 (Cary, NC). The level of statistical signiﬁcance
was set at 0.05 throughout.Table I
List of primers and ampliﬁcation protocols used for qPCR
Target Forward primer Rev
Pro-inﬂammatory TNF-a CTTGTGCCTCAGCCTCTTCTCCTTC CAG
IL-1b GACTGACAAGATACCTGTGGCCT AGA
IL-8 CTTTCTGCAGCTCTGTGTGAAG GCA
Modulatory IL-6 CCTGGTCCAGATCCTGATGCAAAA AAG
Anabolic VEGF TGCAACGACGAGGGCCTA ACT
TGF-b1 CAGCATGTGGAGCTGTACCAGAAA TGA
IGF-1 GTGTGTGGAGACAGGGGCTTTTAT ACT
Reference UBQ TAGCAGTTTCTTCGTGTCCGT TGTResults
The level of mRNA in the control wells at the 3 h timepoint for
one of the three experiments was too low to analyze and the ratios
between stimulated vs control could not be used. Thus, at the
3 h timepoint, only anN¼ 2 is used for analysis of our data. This was
acceptable for the statistical analyses we performed.
eBM-MSC response to LPS stimulation
LPS stimulation provoked a rapid but transient increase in the
transcription of TNF-amRNA in eBM-MSCs after 1 h (23 fold (9.6e
56.4), P < 0.0001, n ¼ 3) and 3 h (seven fold (2.3e19.6), P ¼ 0.001,
n ¼ 2) when compared to control non-stimulated cells [Fig. 1(A)].
Whereas no change in IL-1b gene expression occurred [Fig. 1(B)], a
rapid increase in the transcription of IL-8 mRNA was observed
following LPS stimulation relative to unstimulated controls
[Fig. 1(C)] at the earliest timepoint of 1 h (nine fold (3.6e22.9),
P < 0.0001, n ¼ 3) and persisted at all timepoints to 24 h (3 h: nine
fold (3.2e27.3), P ¼ 0.0003, n ¼ 2, 6 h: ﬁve fold (1.9e12.3),
P¼ 0.002, n¼ 3,12 h: 13 fold (5.0e32.2), P< 0.0001, n¼ 3, 24 h: six
fold (2.2e14.5), P ¼ 0.0008, n ¼ 3). eBM-MSCs stimulated with LPS
signiﬁcantly up-regulated IL-6 at 3 h only (510 fold (19.1e13638.4),
P ¼ 0.0007, n ¼ 2) relative to controls [Fig. 1(D)]. IL-1b, VEGF, TGF-
b1 and IGF-1 gene expression did not change following exposure of
eBM-MSC to LPSwhen comparedwith unstimulated controls at any
timepoint [Fig. 2(AeC)].
eBM-MSC response to IL-1b stimulation
Stimulation with IL-1b induced an increase in IL-1b, which was
signiﬁcant at 1 h (10 fold (2.9e31.6), P ¼ 0.0007, n¼ 3) and 12 h (11
fold (3.3e35.1), P ¼ 0.0005, n ¼ 3) in comparison to controls
[Fig. 1(B)]. A signiﬁcantly enhanced expression of IL-8 was also
observed when eBM-MSCs were stimulated with IL-1b at 1 h (ﬁve
fold (1.9e11.9), P ¼ 0.002, n ¼ 3), 3 h (seven fold (2.3e19.8),
P ¼ 0.001, n ¼ 2), 12 h (nine fold (3.3e21.5), P ¼ 0.0001, n ¼ 3) and
24 h (10 fold (3.9e25.3), P < 0.0001, n ¼ 3) [Fig. 1(C)]. TNF-a, IL-6,
VEGF, TGF-b1 and IGF-1 gene expression did not change following
exposure of eBM-MSCs to IL-1bwhen compared with unstimulated
controls at any timepoint [Figs. 1(A and D) and 2(AeC)].
eBM-MSC response to SF stimulation
IL-1b expression was signiﬁcantly down-regulated after
24 h exposure to NSF andOASF (NSF: 0.10 fold decrease (0.031e0.33),erse primer Ampliﬁcation protocol
CTGGTTGTCTGTCAGCTTC 95C 10 min (polymerase activation),
55 cycles of 95C 15 s, 55C 25 s, 72C 35 s
CAACAGTGAAGTGCAGCCT 95C 10 min (polymerase activation),
55 cycles of 95C 15 s, 55C 25 s, 72C 25 s
GACCTCAGCTCCGTTGAC 95C 10 min (polymerase activation),
50 cycles of 95C 15 s, 63C 25 s, 72C 20 s
GCTTCGAAGGATGAGGTGAGT 95C 10 min (polymerase activation),
65 cycles of 95C 15 s, 56C 25 s, 72C 20 s
GTTCGGCTCCGCCA 95C 10 min (polymerase activation),
65 cycles of 95C 15 s, 59C 25 s, 72C 20 s
CATCAAAGGACAGCCATTCCG 95C 10 min (polymerase activation),
55 cycles of 95C 15 s, 55C 25 s, 72C 25 s
TCCTTCTGAGCCTTGGGCATA 95C 10 min (polymerase activation),
55 cycles of 95C 15 s, 55C 20 s, 72C 20 s
AATCGGAAAGAGTGCGG 95C 10 min (polymerase activation),
50 cycles of 95C 15 s, 60C 25 s, 72C 20 s
Fig. 1. eBM-MSCs’ expression of paracrine pro-inﬂammatory and modulatory signaling molecules implicated in the pathology of OA is inﬂuenced by stimulation with LPS or IL-1b
in vitro. LPS signiﬁcantly increased the transcription of (A) TNF-a at 1 h (23 fold (9.6e56.4), P < 0.0001, n ¼ 3) and 3 h (seven fold (2.3e19.6), P ¼ 0.001, n ¼ 2), (C) IL-8 at all
timepoints (1 h: nine fold (3.6e22.9), P < 0.0001, n ¼ 3, 3 h: nine fold (3.2e27.3), P ¼ 0.0003, n ¼ 2, 6 h: ﬁve fold (1.9e12.3), P ¼ 0.002, n ¼ 3, 12 h: 13 fold (5.0e32.2), P < 0.0001,
n ¼ 3, 24 h: six fold (2.2e14.5), P ¼ 0.0008, n ¼ 3) and (D) IL-6 at 3 h (510 fold (19.1e13638.4), P ¼ 0.0007, n ¼ 2) compared to unstimulated eBM-MSCs but (B) IL-1b expression was
not affected by this stimulation. Conversely, IL-1b stimulation signiﬁcantly increased the transcription of (B) IL-1b at 1 h (10 fold (2.9e31.6), P ¼ 0.0007, n ¼ 3) and 12 h (11 fold
(3.3e35.1), P ¼ 0.0005, n ¼ 3) and (C) IL-8 at 1 h (ﬁve fold (1.9e11.9), P ¼ 0.002, n ¼ 3), 3 h (seven fold (2.3e19.8), P ¼ 0.001, n ¼ 2), 12 h (nine fold (3.3e21.5), P ¼ 0.0001, n ¼ 3) and
24 h (10 fold (3.9e25.3), P < 0.0001, n ¼ 3) but (A) TNF-a and (D) IL-6 expression was unchanged by IL-1b stimulation compared to unstimulated eBM-MSCs. Open circles represent
LPS-treated eBM-MSCs, solid circles represent IL-1B-treated eBM-MSCs and * represent statistically signiﬁcant fold increases (P  0.05).
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n ¼ 3) relative to controls [Fig. 3(B)]. Stimulation of eBM-MSCs with
OASF, but not NSF, induced a rapid, but transient, signiﬁcant increase
(three fold (1.49e4.97), P¼ 0.002, n¼ 3) in the levels of VEGF mRNA
after 1 h in culture [Fig. 4(A)]. TNF-a, IL-8, IL-6, TGF-b1 and IGF-1 gene
expression did not change following exposure of eBM-MSCs to OASF
when compared with NSF at any timepoint [Figs. 3(A, C and D) and
4(B and C)]. The anabolic cytokines TGF-b1 and IGF-1 gene expres-
sion was not signiﬁcantly up-regulated by exposure to either NSF or
OASF [Fig. 4(B and C)].
Discussion
Several important ﬁndings on eBM-MSC paracrine cytokine re-
sponses, relevant to their IA therapeutic applications, wereidentiﬁed in the current investigation modeling inﬂammatory joint
conditions. First, the eBM-MSC pro-inﬂammatory cytokine gene
expression was up-regulated when exposed to inﬂammatory
stimuli and was agonist dependent: LPS stimulation enhanced
eBM-MSC expression of the pro-inﬂammatory cytokine TNF-a and
also the predominantly chemotactic cytokine IL-8, in addition to
the modulatory cytokine IL-6, but not IL-1b. Stimulation with IL-1b
also up-regulated IL-8 gene expression. However, the IL-1b stim-
ulus enhanced eBM-MSCs’ IL-1b gene expression, providing evi-
dence for a positive feedback loop. Second, the inﬂammatory
molecules did not increase nor decrease eBM-MSCs’ expression of
any of the anabolic genes studied, namely VEGF, IGF-1 and TGF-b1.
Third, unlike the inﬂammatory molecules LPS and IL-1b, OASF did
not up-regulate the eBM-MSC pro-inﬂammatory genes, but instead,
induced a signiﬁcant up-regulation in VEGF. Combined these
Fig. 2. eBM-MSCs’ expression of the paracrine anabolic signaling molecules implicated
in the pathology of OA is unaffected by stimulation with LPS or IL-1b. (A) VEGF, (B)
TGF-b1 and (C) IGF-1 gene expression is not signiﬁcantly different in cultured eBM-
MSCs stimulated with LPS or IL-1b compared to unstimulated eBM-MSCs. Open cir-
cles represent LPS-treated eBM-MSCs, solid circles represent IL-1B-treated eBM-MSCs
and * represent statistically signiﬁcant fold increases (P  0.05).
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modify their secretory phenotype to different inﬂammatory cues in
their environment. Of importance from a clinical perspective, no
adverse pro-inﬂammatory effects were identiﬁed when eBM-MSCs
were exposed to OASF but instead an anabolic effect was identiﬁed.LPS and IL-1b stimulation underpins BM-MSCs capacity to
contribute to inﬂammation
The results of the LPS and IL-1b stimulations of eBM-MSCs are in
agreement with previous investigators that MSCs are sensitive to
hostile microenvironments10,16,24e26. LPS signals through the toll-
like receptor TLR425,26. Toll-like receptors are important for the
innate and adaptive immune system responses as they recognize
both pathogen and damage-associated molecular patterns. The
rapid and transient increase in eBM-MSC TNF-a transcription in
response to LPS is comparable to the response observed in human
monocytes27, suggesting some analogous functions of MSCs and
cellular effectors of the innate immune system as suggested by
others24,26. TNF-a plays a major role in joint inﬂammation11 and
this ﬁnding reveals a capacity of resident MSCs to contribute to
inﬂammation in the acute phase, at least in the presence of sepsis.
IL-8 gene expression, on the other hand, was augmented
throughout the 24 h stimulation period and to a similar degree on
stimulation with the pro-inﬂammatory cytokine IL-1b, consistent
with a previous study employing of hMSCs25. IL-8 is chemotactic for
neutrophils, modulates their secretory response and is angio-
genic28. This IL-8 response is also in line with MSCs pro-
inﬂammatory role and conﬁrms and extends the ﬁndings of
others24,26. The sharp and sustained increase in IL-8 expression
suggests that MSCs may amplify the communication between
injured or inﬂamed tissues and the cells of the innate immune
system, and therefore contribute to tissue neutrophilia.
The inability of LPS stimulation (100 ng/ml) to enhance IL-1b
gene expression in eBM-MSCs contrasts markedly with data from
hMSCs, where 4 h stimulation with 10 ng/ml of LPS increased IL-1b
gene expression 135 fold25. This differential response may be
explained by putative evolutionary divergence in the TLR4 genes,
which may affect the nature of downstream intracellular signaling
events in different species29. Moreover, the above-described dis-
crepancies may be caused by the 10 fold increase in LPS concen-
tration used in our experiments.
IL-1b stimulation induces a pro-inﬂammatory signature in BM-MSC
IL-1b is the principal instigator of articular cartilage degradation
in OA through protease induction and has been identiﬁed in both
osteoarthritic cartilage and SF12,3032. Consequently MSCs employed
for therapeutic purposes IA in OA would be exposed to this pro-
inﬂammatory cytokine. The stimulation of MSCs by IL-1b caused
an up-regulation of IL-8 similar to LPS, but, unlike LPS, also caused a
biphasic up-regulation of IL-1b and no up-regulation of IL-6. The
cellular receptors for LPS and IL-1b are closely interlinked and
described as the TLR-IL-1 receptor (IL-1R) superfamily of receptors.
When activated they induce a series of intercellular signaling path-
ways that converge on the transcription factor nuclear factor KappaB
(NF-KappaB) resulting in pro-inﬂammatory cytokine expression9,33.
These results suggest that the induction of IL-8 arises potentially
from similar intracellular pathways but the differential IL-1b
response and absence of IL-6 response to IL-1b may indicate alter-
native receptor signaling effects or either dose or time dependent
effects. Nonetheless, both stimuli, LPS and IL-1b, induced the eBM-
MSCs to adopt a pro-inﬂammatory phenotype. From a clinical
standpoint this is particularly important in respect to IL-1b as it is
present in OA joint tissues and indicates that eBM-MSCs could
potentially contribute to the inﬂammatory processes in joint disease.
Together, the results reveal that eBM-MSCs have the capacity,
depending on the joint environmental conditions, to contribute to
joint inﬂammation by up-regulation of transcription of all the pro-
inﬂammatory cytokines we investigated, i.e., TNF-a, IL-1b, IL-8 and
IL-6. Furthermore, neither of the inﬂammatory stimuli, LPS or IL-1b,
Fig. 3. eBM-MSCs’ expression of paracrine pro-inﬂammatory and modulatory signaling molecules implicated in the pathology of OA is inﬂuenced by stimulation with NSF or OASF.
(A) TNF-a, (C) IL-8 and (D) IL-6 gene expression at all timepoints was not signiﬁcantly different in cultured eBM-MSCs stimulated with SFs from either normal or OA joints. However,
the transcription of (B) IL-1b at 24 h was signiﬁcantly decreased upon stimulation with both NSF and OASF (NSF: 0.10 fold decrease (0.031e0.33), P ¼ 0.0006, n ¼ 3; OASF; 0.07 fold
decrease (0.023e0.24), P ¼ 0.0002, n ¼ 3) compared to unstimulated eBM-MSCs. Open triangles represent NSF-treated eBM-MSCs, solid triangles represent OASF-treated eBM-MSCs
and * represent statistically signiﬁcant fold decreases (P  0.05).
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cytokines. The apparent discrepancy between these results and a
recent study employing hMSC where VEGF was down-regulated by
LPS stimulation, may be due to different concentrations of agonists
or duration of stimulation25.
OASF does not induce a BM-MSC pro-inﬂammatory cytokine proﬁle
Importantly, unlike LPS and IL-1b stimulation, none of the pro-
inﬂammatory cytokines were up-regulated by in vitro stimulation
of eBM-MSCs with either NSF or OASF. This suggests that a
component of SF acts on BM-MSCs to down-regulate the expres-
sion of IL-1b, one of the most important pro-inﬂammatory
cytokines produced in OA joints, thereby evading an MSC pro-
inﬂammatory phenotype, but the mechanism by which it acts
requires elucidation. Inherent anti-inﬂammatory properties of SFmay also account for the ﬁnding that eBM-MSCs’ expression of
pro-inﬂammatory cytokines were not up-regulated following
stimulation with OASF. However, it is important to point out that
the fold changes were very modest in the study herein, as ex-
pected, when compared to the effects observed with LPS or IL-1b
stimulation alone. Overall, this lack of induction of an MSC pro-
inﬂammatory phenotype on exposure to OASF is encouraging
news from a clinical perspective. However caution should be
exercised in interpreting the data. OASF composition will be var-
iable depending on the disease status at aspiration, joint and age
and these combined variables mean that a different response may
have been elicited if other SF samples had been employed e.g.,
early vs late stage of disease. Additional characterization of the OA
SF inﬂammatory status by routine (total protein and leukocyte
counts) and inﬂammatory cytokine analysis could have provided
important information about its composition. Furthermore, the
Fig. 4. eBM-MSCs’ expression of the paracrine anabolic signaling molecule VEGF is
signiﬁcantly up-regulated on exposure to OASF for 1 h. (A) VEGF levels are signiﬁcantly
increased upon stimulation with OASF at 1 h (three fold (1.49e4.97), P ¼ 0.002, n ¼ 3)
but not longer stimulations whereas (B) TGF-b1 and (C) IGF-1 levels are not signiﬁ-
cantly different in cultured eBM-MSCs stimulated with either NSF or OASF compared
to unstimulated controls at any timepoint. Open triangles represent NSF-treated eBM-
MSCs, solid triangles represent OASF-treated eBM-MSCs and * represent statistically
signiﬁcant fold increases (P  0.05).
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history (treatment or clinical signs).
It could also be argued that the 10% dilution of SF employed for
the stimulations of eBM-MSCs in culture resulted in dilution effects
and subthreshold concentrations of IL-1b. A 10% dilution was
employed to facilitate manipulation and mixing due to the natural
high viscosity of SF. Other groups have previously reported signif-
icant effects of SF at these (and lower) dilutions, on various bio-
logical processes such as the transcriptional activity, migration and
differentiation of cultured MSCs10,19,34e36. If it had been possible to
use 100% SF, the observed effects may have been enhanced or
additional effects may have been identiﬁed. IL-1b stimulation was
employed to compensate for this dilution, as it is known to be
present in OASF2. The lack of robust differences between the groups
of NSF and OASF may also be due to the small n values (n¼ 3) in the
study design.
Other investigators have recently observed an up-regulation of
IL-6 on exposure of MSCs to 20% OASF10. IL-6 is a pleiotropic
cytokine with some pro-inﬂammatory actions but also involved in
regenerative processes and regulation of metabolism37,38. There are
a number of possible explanations for the apparent discrepancy
between our results and the recent ﬁndings of Leijs et al., who
observed a twofold up-regulation of IL-6 following 48 h of stimu-
lation. It may be explained by the different timepoints assessed and
also possible differences in joint ﬂuid composition related to the
stage of the OA disease process. We investigated multiple time-
points up to 24 h whereas Leijs and colleagues studied only one
timepoint at 48 h10.
OASF induces a BM-MSC anabolic cytokine proﬁle
The gene expression of the anabolic cytokines VEGF, TGF-b1
and IGF-1 were investigated in the study herein as they are all
believed to have a positive anabolic role for joint repair39. VEGF
is a potent angiogenic factor that possess anti-apoptotic effects
and that promotes the neovascularization of injured sites9,40e43.
The up-regulation of VEGF observed on exposure to OASF sug-
gests that OASF may promote a healing response through the
mechanisms outlined above. MSCs’ capacity to up-regulate VEGF
in the presence of disease has already been demonstrated in a
murine model of ischemia44. This modest, yet signiﬁcant, change
in VEGF expression was not induced by stimulation with NSF,
indicating that eBM-MSCs respond differentially to NSF
compared to OASF.
Conclusion
In conclusion, the present ﬁndings add to the very limited
knowledge of the behavior of BM-MSCs in response to changes in
SF composition that occur in OA. BM-MSCs can adopt a pro-
inﬂammatory or anabolic phenotype depending on environ-
mental cues. Although the pro-inﬂammatory cytokine IL-1b, a key
player in OA degradative events, induced a BM-MSC pro-inﬂam-
matory phenotype, OASF, on the other hand, promoted VEGF
expression without any pro-inﬂammatory cytokine induction.
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